"Menstrual induction" with Sulproston.
The PGE2-analogue Sulproston (16-phenoxy-omega-17,18,19,20-tetranor-PGE2-mythylsulfonylamide) was administered to 200 medically and gynecologically normal women who were 17 +/- 0.4 days beyond their expected menstrual period and who had a positive pregnancy test. The intramuscular impact dose (500 micrograms repeated after 4 hours) caused an immediate tonic uterine contraction which compromised the estradiol 17 beta, progesterone and chorionic gonadotropin production within the fetoplacental unit, and thereby allowed the evolution of cyclic uterine activity, cervical dilatation and tissue expulsion. Pregnancy termination was complete in 92% of women, 5.5% required surgical curettage and 2.5% were given a second Sulproston treatment 2-3 weeks after the first to remove retained tissue from the uterus. The medical induction of menstruation was preferred by 83% of the women who had previously experienced surgical termination of pregnancy. Normal menstruation resumed in all women after 36 +/- 0.9 days. The majority of 42 women questioned found Sulproston a satisfactory, safe, simple and effective drug regimen for "menstrual induction".
D000020:Abortifacient Agents, Nonsteroidal; D000028:Abortion, Induced / Q000379:methods*; D006063:Chorionic Gonadotropin / Q000097:blood; D015232:Dinoprostone / Q000031:analogs & derivatives*; D004958:Estradiol / Q000097:blood; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D008598:Menstruation / Q000187:drug effects*; D008600:Menstruation-Inducing Agents; D011247:Pregnancy; D011374:Progesterone / Q000097:blood; D011459:Prostaglandins E, Synthetic / Q000494:pharmacology / Q000627:therapeutic use*; D014463:Ultrasonography
D000020:Abortifacient Agents, Nonsteroidal; D006063:Chorionic Gonadotropin; D008600:Menstruation-Inducing Agents; D011459:Prostaglandins E, Synthetic; D011374:Progesterone; D004958:Estradiol; C016767:sulprostone; D015232:Dinoprostone